Bond.az White LogoBond.az Black Logo

Rosenblatt Cuts Canaan Target Price to $1.30

Rosenblatt cuts Canaan stock price target to $1.30 from $2.25, maintains Buy rating. Canaan faces revenue miss in Q1 FY2026.

Mia Lopez
ByMia Lopez- Senior Editor
|
0

Rosenblatt lowered its price target on Canaan Inc. (NASDAQ:CAN) to $1.30 from $2.25 while maintaining a Buy rating on the stock. The target suggests substantial upside from the current price of $0.42, which sits near its 52-week low of $0.39.

The firm noted that Canaan reported revenue in line with guidance despite declining bitcoin prices and increasing energy costs. Profitability suffered during the period, with the company posting a gross profit margin of just 7.77% in the last twelve months.

Rosenblatt said management is making strategic moves toward becoming a more vertically integrated bitcoin miner. The company is also diversifying into home markets and cutting costs.

The firm lowered its revenue estimates for Canaan. The new 12-month price target reflects the reduced revenue projections.

Canaan manufactures bitcoin mining equipment and operates mining operations. According to fair value analysis, the stock appears undervalued at current levels.

In other recent news, Canaan Inc. reported its first-quarter fiscal 2026 earnings, revealing a revenue of approximately $62.7 million, which fell short of the anticipated $64.68 million. The company also reported an earnings per share (EPS) of -$0.86, significantly missing the forecast of -$0.03. Despite these results, BTIG reiterated a Buy rating for Canaan, maintaining a price target of $3.00.

More News
Today / 12:32
|
782

Deutsche Bank upgrades Centene stock on earnings recovery

Deutsche Bank upgrades Centene stock to Buy with a new price target of $80. Bond.az analysis highlights undervaluation. Latest news on Centene.

0
Today / 12:31
|
743

Deutsche Bank upgrades Elevance stock

Deutsche Bank upgraded Elevance Health to Buy with a $498 price target, citing stable managed care market. Strong Q1 results also boost confidence.

0
Today / 12:11
|
261

BMO Raises Israel Chemicals Target Price on Potash

BMO Capital raises Israel Chemicals price target to $6.50 on strong potash outlook and higher EBITDA guidance.

0
Today / 12:10
|
222

Cantor Fitzgerald raises PANW price target to $285

Cantor Fitzgerald raises Palo Alto Networks price target to $285, citing platformization, AI tailwinds, and strong partner results.

0
Today / 11:53
|
435

Stifel Maintains Manhattan Associates Price Target

Stifel maintains Buy rating and $200 target for Manhattan Associates. The company is investing in cloud migration and agentic AI capabilities.

0
Today / 11:52
|
256

Rosenblatt Raises 8x8 Target to $3.00

Rosenblatt raises 8x8 stock target to $3.00 after strong Q4 results. Revenue beat guidance.

0
Today / 11:52
|
385

Piper Sandler Reiterates Alphabet Overweight on AI

Piper Sandler reiterates Alphabet Overweight rating and $425 target after Google I/O AI product launches.

0
Today / 11:50
|
872

Bernstein raises Dell target to $280 on AI

Bernstein raises Dell price target to $280, citing agentic AI demand and SMCI share losses.

0
Today / 11:43
|
228

Alpha Tau Stock Gets Buy Rating, $15 Target

H.C. Wainwright reiterates Buy on Alpha Tau stock with $15 target. Company completes ReSTART trial enrollment.

0
Today / 11:42
|
472

H.C. Wainwright Reiterates Protara Buy Rating

H.C. Wainwright reiterates Buy rating on Protara Therapeutics (TARA) with $27 target. Encouraging results from lymphatic malformation and bladder cancer trials.

0
Today / 11:41
|
612

H.C. Wainwright reiterates MindWalk stock rating on platform validation

H.C. Wainwright reiterates Buy rating and $5 target on MindWalk stock, citing platform validation and strong pipeline. Read more.

0
Today / 11:40
|
376

Traws Pharma Gets $8 Price Target from H.C. Wainwright

H.C. Wainwright reaffirms Buy on Traws Pharma with $8 target. Financing secured for influenza drug trial. Read more on Bond.az.

0
...